Clinical Trials Browser

Interventional × Has results × rilotumumab × Clear all

NCT00791154 2024-08-23

SCLC

Phase 1/2 Terminated

213 enrolled 16 charts

Lung Neoplasms, Pleural Effusion, Malignant, Small Cell Lung Carcinoma

NCT00788957 2024-08-07

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Phase 1/2 Completed

177 enrolled 31 charts

Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02926638 2020-03-19

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Phase 2/3 Terminated

9 enrolled 5 charts

MET Positive

NCT01039207 2017-09-07

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 2 Completed

31 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01233687 2017-06-22

AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer

Phase 1/2 Completed

49 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT01113398 2015-12-10

AMG 102 and Avastin for Recurrent Malignant Glioma

Phase 2 Completed

36 enrolled 9 charts

Glioblastoma, Glioma, Recurrence, Gliosarcoma